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Abstract  
 
Background: Transcutaneous electrical acupoint stimulation (TEAS) is thought to have 
potential to treat obsessive-compulsive disorder (OCD).  
Objective: The purpose of this study was to determine whether adding TEAS to 
cognitive behavioral therapy (CBT) and clomipramine would improve the efficacy of 
these conventional treatments in OCD. 
Methods: In this randomized controlled trial, 360 OCD patients were assigned to receive 
TEAS combined with CBT plus clomipramine (Group A, n = 120), TEAS combined 
with CBT plus placebo (Group B, n = 120), and simulated (placebo) TEAS combined 
with CBT plus clomipramine (Group C, n = 120) for 12 weeks. The primary outcome 
was measured using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS).  
Results: OCD symptoms in all patients reduced over time, however Groups A and B had 
a significantly greater reduction in Y-BOCS total score and the subscale for obsession 
and compulsion between week 2 and week 12 compared to Group C. Groups A and B 
had similar scores on these measures. Both groups had significantly higher rates of 
clinical response than Group C (88.3% and 81.7% vs. 67.5%, respectively, p < 0.001); 
and higher rates of remission (30.0% and 22.5% vs. 9.2%, respectively, p < 0.001). 
Group B experienced fewer adverse events than the other two groups.  
Conclusions: TEAS enhances the efficacy of conventional OCD interventions and 
avoids the adverse effects associated with conventional pharmacological treatment. It 
can be considered as an effective adjunct intervention for OCD.  
 
Keywords: Obsessive compulsive disorder (OCD); transcutaneous electrical acupoint 
stimulation (TEAS); transcutaneous electrical nerve stimulation (TENS); serotonin 
reuptake inhibitors (SRIs); cognitive behavioral therapy (CBT); clomipramine.  
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1. Introduction 
 
Obsessive-compulsive disorder (OCD) is a disabling mental illness that affects 
approximately 1-2% of the general population (Lihua et al., 2013; Ruscio et al., 2010). It 
is characterized by recurrent, intrusive and senseless thoughts (obsessions) and/or 
excessive repetitive behaviors (compulsions) aimed at reducing the associated anxiety 
(APA, 2000). Despite the fact that serotonin reuptake inhibitors (SRIs), such as 
clomipramine, and cognitive behavioral therapy (CBT) are recommended as first-line 
treatments for OCD (Pizarro et al., 2014; Romanelli et al., 2014), there still remains a 
large portion of the patients who do not make a full response (Schruers et al., 2005). A 
search for alternative strategies is thus important.    
 
Although it is an ancient therapeutic technique, acupuncture has been increasingly 
included in the management of neurological and psychiatric disorders, such as pain, 
insomnia, anxiety and depression (Pilkington, 2013; van der Watt et al., 2008). 
Acupuncture methodology has also evolved along with the advances in modern science 
and technology (Han, 2011; Han et al., 1994; Han and Ho, 2011). Transcutaneous 
electrical acupoint stimulation (TEAS) has been developed to replace needle penetration 
(Han et al., 1994). TEAS is a form of transcutaneous electrical nerve stimulation 
(TENS), TEAS may be more effective than other forms of TENS in modulating brain 
activity, as acupoints contain relatively denser neural and neuroactive components than 
non-acupoint areas (Zhang et al., 2012). Unlike invasive acupuncture in which needles 
are inserted into acupoints on the body, TEAS is a non-invasive electrical stimulation 
that generally could not cause pain and needle phobia (Wang et al., 1992; Han, 2011). 
While TEAS is practiced in a noninvasive, safer and time-saving manner, its 
antinociceptive potency is reported to be equivalent to that of needling acupuncture with 
both approaches sharing similar mechanisms (Wang et al., 1992; Han, 2011). TEAS has 
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now been reported to have a beneficial effect in autism (Zhang et al., 2012), smoking 
cessation (Lambert et al., 2011), and drug dependence (Meade et al., 2010; Penetar et al., 
2012). We and others have the preliminary evidence for the effectiveness of TEAS 
together with CBT and/or SRIs in phobia and OCD (Feng et al., 2005, 2006; Yamashita 
et al., 1991).  
 
In this study we tested the hypothesis that adding TEAS to CBT and SRIs would 
improve the efficacy of these conventional treatment in OCD. To achieve this, we 
compared the outcomes of patients randomized to three treatment groups: Group A, 
TEAS + CBT + clomipramine; Group B, TEAS + CBT + placebo; and Group C, 
simulated TEAS + CBT + placebo, using a double-blind, controlled design. 
Clomipramine is a commonly prescribed SRI for OCD with well-established efficacy for 
the treatment of OCD (Pizarro et al., 2014).  
 
2. Materials and methods 
 
2.1. Settings and participants 
This multisite, partially double-blind, randomized controlled trial was conducted 
between September 2009 and December 2012 in 3 hospitals: Zhejiang Provincial 
Tongde Hospital, Yiwu Hospital of Traditional Chinese Medicine (TCM), and Wuxi 
Mental Health Center. The study protocol was approved by Medical Ethical Committee 
of all hospitals involved and registered in www.chictr.org (ChiCTR-TRC-09000484), a 
member of the WHO International Clinical Trial Registry Platform. The study was 
carried out in accordance with the approved protocol. All participants and/or their 
guardians gave voluntary, written, informed consent before entering the trial. 
Both outpatients and inpatients were invited to participate in the study. Eligible subjects 
were (1) either gender aged 16-65 years with (2) a principal diagnosis of OCD of 
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duration ≥?1 year, according to the Classification of Mental and Behavior Disorders 
(10th version) (ICD-10) (WHO, 1995). (3) The severity of participants’ symptoms was 
at least moderate, as evidenced by the Yale-Brown Obsessive-Compulsive Scale (Y-
BOCS) total score of ≥?16 (Farris et al., 2013; Goodman et al., 1989a,b); and (5) All had 
capacity to give written informed consent.   
 
Patients who had any of the following conditions were excluded: (1) OCD was only a 
comorbid symptom, but the “primary” psychiatric disorders were not OCD. The 
“primary” disorders included schizophrenia, mood disorders, tic disorders, movement 
disorders, eating disorders, and mental retardation; (2) severe cardiovascular, hepatic, 
renal condition, or narrow-angle glaucoma; (3) a history of brain injury or surgery; (4) a 
history of suicide attempts or aggressive behavior; (5) pregnancy or lactation; (6) 
laboratory tests of hepatic and renal function and/or electrocardiogram (ECG) 
significantly beyond the normal reference ranges; (7) investigational drug treatment 
within the previous 6 months; (8) a history of alcohol or drug abuse within the previous 
12 months; or (9) heart pacemaker or other metal devices implanted in the body.  
 
2.2. Randomization and blinding 
Patients were randomly allocated to 1 of 3 groups: Group A, TEAS combined with CBT 
plus clomipramine; Group B, TEAS combined with CBT plus placebo tablets (Group B); 
and Group C, simulated TEAS combined with CBT plus clomipramine (Group C) in a 
ratio of 1:1:1. For randomization, simple, complete, non-sequential random codes were 
produced in advance using a computer-generated block scheme in which treatment 
groups were kept in balance for every 6 entrants at each site. Drug dispensers, clinical 
raters, data collectors and analysts were blinded to the treatment; behavioral therapists 
were blinded to patients’ medications and TEAS (see below).  
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The group allocation was done in a double-blind manner. For medications, random 
codes were printed on boxes containing clomipramine and placebo tablets. All study 
personnel, including drug dispenses, clinical assessors, data collector and analysts, were 
blind to patients’ medication status. However, assignment to TEAS or stimulated 
stimulation was known to the therapists who carried out these procedures, but no other 
personnel. Patients were not aware of their assignment to either TEAS or simulated 
stimulation. They were told that they would receive electrical stimulation on both hands, 
but they were not told that the stimulation might be simulated or real. Behavioral 
therapists, clinical assessors and psychiatrists communicated with patients separately 
and were instructed not to acquire information about their other treatment conditions.  
 
2.3. Intervention  
Clomipramine treatment: Both clomipramine and placebo tablets were manufactured by 
Hunan Dongting Pharmaceutical Co., Ltd. (Changsha, Hunan, China). Both were 
prepared to be identical in appearance, odor, flavor and color. Clomipramine was 
initiated at a dosage of 25 mg/day and titrated up to a maximum of 150 mg/day within 
16 days, depending on clinical and side effects. This dosing regimen of clomipramine 
has been well established to achieve a balance between the therapeutic benefits and 
adverse effect risk for the treatment of OCD in Chinese population (Feng et al., 2006). 
Group A and C received clomipramine treatment; Group B was given matching placebo 
tablets.  
 
Those who were currently treated with clomipramine continued their clomipramine 
treatment, but the dose would not exceed 150 mg/day. Those who were currently treated 
with other anti-OCD drugs were instructed to switch to the clomipramine treatment 
regimen by gradually withdrawing the current drugs within one week. This washout 
period was sufficient to eliminate carryover effects of most antipsychotics and selective 
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serotonin reuptake inhibitors (SSRIs) (Hiemke & Härtter, 2000; Mauri et al., 2014). 
Concomitant use of other psychoactive agents was not allowed. Medication compliance 
was determined with tablet count at each visit. Patients required concomitant 
medications and those with <80% compliance were advised to withdraw from the study.  
 
CBT: Patients from all 3 groups received CBT consisting of exposure and response 
prevention (EX/RP) according to standard care in OCD (Franklin et al., 2002); but the 
number of treatment sessions was adapted to 12 sessions (once weekly) with each 
session lasting 45 min, based on clinical characteristics in Chinese patients with OCD 
and Chinese cultural context (Guo and Lanley, 2015; Ma et al., 2013; Zhang et al., 2013]. 
The adapting CBT has been widely used in China (Guo and Lanley, 2015; Ma et al., 
2013). Briefly, session 1-2 included introduction to the treatment procedure, cognitive 
training and identifying OCD target symptoms. In Session 3-12, patients were instructed 
to face their obsessional fears induced with imagined and real scenarios. Patients were 
always encouraged to actively control and stop obsessive thoughts and ritual behavior 
during the exposure. The intensity of the exposure was gradually increased when anxiety 
had reduced to a negligible level in the preceding trial. A family member was asked to 
be involved in the treatment whenever possible. Homework with at least 30 min of self-
directed exposures daily was assigned between sessions to enhance patients’ motivation 
and prevent relapse.  
 
In order to ensure consistency of CBT delivery across study sites, a pretrial training 
workshop was held for psychiatrists and behavioral therapists who performed CBT. The 
detailed explanation of EX/RP procedure and rehearsal with real patients was conducted 
under the supervision of a senior behavioral therapist (B.F.).   
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TEAS and simulated stimulation: Patients in Group A and B received TEAS and Group 
C received simulated stimulation. TEAS and CBT treatment were conducted 
simultaneously by CBT therapists (Fig. 1). TEAS was delivered on the bilateral Nei-
Guan (PC6) which is located on the anterior forearm, between the tendons of palmaris 
longus and flexor carpi radialis, at the junction of the distal sixth and proximal five 
sixths of the line connecting the middle points of the wrist and elbow crease (Liu & Liu. 
2009). According to traditional Chinese medicine, this acupoint is particularly beneficial 
for sleep, sadness, nervousness, palpitation, chest congestion, nausea and vomiting (Liu 
& Liu. 2009). Neuroimaging studies have shown that acupuncture stimulation on this 
acupoint can modulate a wide range of cortical and limbic brain region activity (Chang 
et al., 2009; Quirico et al., 2014; Yoo et al., 2004; Zhang et al., 2012). Constant-current 
electrical impulses produced from a battery-driven TEAS apparatus (NDK, Osaka, Japan) 
were delivered on bilateral acupoints via two adhesive electrode pads placed on the 
acupoint skin (Fig. 1). The stimulation frequency was set at 50 Hz with pulse width of 
50 µs. The choice of this frequency was based on our preliminary experiments 
comparing acceptability of different frequencies (2-100 Hz). This frequency range has 
also been shown to robustly induce the release of endogenous opiate neuropeptides in 
the central nervous system (Han, 2003). The pulse amplitude (0-100mA) was titrated to 
a level at which the perception of ≥?strong but comfortable’ was achieved.    
 
Transient placebo-TENS was applied for simulated stimulation (Rakel et al., 2010). 
Adhesive electrode pads was placed at sites 1 cm radial to Nei-Guan (PC6) and the 
stimulation intensity are adjusted to the minimal sensory threshold for 30 seconds and 
then ramped off over the next 15 seconds so that it was active for a total of 45 seconds. 
This transient placebo-TENS has been well validated and found to better maintain 
blinding compared to standard placebo-TENS methods, in which no current was actually 
delivered to the electrodes (Rakel et al., 2010).     
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2.4. Treatment outcome measures 
Treatment outcomes were evaluated at baseline, week 2, 4, 8 and 12. The primary 
outcomes were the total score on the Y-BOCS and subscales for obsession and 
compulsion (Goodman et al., 1989a,b). The secondary outcomes were clinical response 
and remission. As previously described (Farris et al., 2013), a clinical response was 
defined as a ≥35% reduction at endpoint from baseline on Y-BOCS total score. 
Remission was defined as an endpoint Y-BOCS score of ≤12. Laboratory tests, 
including hepatic and renal functions, ECG and EEG, were conducted at baseline and 
the completion of treatment. Safety was assessed using the Treatment Emergent 
Symptom Scale (TESS) (Guy 1976), in which adverse events that first appeared during 
the study or worsened relative to the pre-study status were recorded at each visit, 
including date and time of onset, duration, severity, relationship to intervention, and 
action taken accordingly.  
 
Clinical assessment was performed by three raters (F.Z.X., L.X.Z., and Y.Y.L.) who 
were blinded to the treatment. To ensure consistency of assessment across sites, a 
training workshop was carried out on videotaped patients with OCD before the 
recruitment started. Independent assessors from all study sites had achieved an inter-
rater reliability coefficient (κ value) of >0.80 on Y-BOCS after the completion of 
training workshop. In most cases, all assessments of a subject from baseline to endpoint 
were conducted by the same assessor in order to minimize potential variations caused by 
different assessors.   
 
2.5. Statistical analysis 
The sample size estimation was based on clinical response rate. Based on our previous 
studies (Feng et al., 2005, 2006), we expected that the addition of TEAS could produce 
an approximately 20% higher clinical response rate than simulate stimulation. A sample 
size of 360 was calculated to provide an approximately 90% power at a statistical level 
of 0.01.    
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Data analysis was conducted by H.K.W. who was blinded to the treatment. Efficacy 
analyses were performed on the intention-to-treat population, defined as participants 
who completed baseline and at least one evaluation after treatment. A linear mixed-
effect model was applied to compare the primary treatment outcomes (Y-BOCS and its 
subscales for obsession and compulsion) over time among the 3 groups. The model was 
established using time and group for categorical fixed factors and random intercepts 
with scaled identity covariance matrix. Subject’s age, gender and baseline Y-BOCS 
served as covariates. One-way analysis of variance (ANOVA) was further used to detect 
between-group differences among the 3 groups in continuous variables. Categorical 
variables, including categorical baseline variables, response and remission rates, and 
incidence of adverse events were analyzed using Chi-square (χ2) test. Statistical 
significance was defined as a two-tailed P < 0.05. The analysis was conducted with 
SPSS version 19.0 software (SPSS Inc., Chicago, IL, USA).  
 
3. Results 
 
3.1. Participant characteristics  
Of 1435 patients screened, 360 eligible patients were recruited from Tongde Hospital (n 
= 200), Yiwu Hospital of TCM (n = 80) and Wuxi Mental Health Center (n = 80). The 
patients were randomly assigned to one of the three groups (n = 120 each); 335 (93.1%) 
completed the full 12 weeks of treatment and assessment (Fig. 2); 6.9% (25/360) 
discontinued treatment. No statistically significant difference was observed among the 
three groups in discontinuation rate (Fig. 2).  
 
The sample was representative of young adults with OCD, as indicated by the mean (SD) 
age of 33.7 (·12.4) years, the mean duration of the illness of 5.0 (·5.6) years and the 
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Y-BOCS severity of 27.0 (·5.3) indicative of moderate to severe illness. A majority of 
patients (68.1%, 245/360) were under psychotropic medication when entering the study; 
only 2 were being treated with clomipramine. A small percentage of patients (6.1%, 
22/360) had a diagnosis of comorbid psychiatric disorders. There were no statistically 
significant differences in baseline variables among the three groups (Table 1) or among 
the three study sites (data not shown). No participants received CBT when they entered 
the trial.   
 
Overall medication compliance was approximately 95% across the three groups. No 
patients were excluded due to the poor compliance (less than 80%). The mean doses of 
clomipramine taken were 143.9 (17.6) mg/day for Group A and 141.7 (21.3) mg/day for 
group C (t1,238 = 0.884, P = 0.378). Those who completed the full 12 weeks of treatment 
also completed the full CBT sessions as per protocol.   
 
3.2. Treatment outcomes  
The primary outcomes are illustrated in Table 2 and Fig. 3. Linear mixed-effect model 
revealed significant differences in the slope among the 3 groups on total Y-BOCS (F = 
9.128, p = 0.0001), obsession (F = 5.755, p = 0.0032) and compulsion (F = 13.389, p < 
0.0001). The three variables strikingly reduced over the course of treatment for each 
group (p < 0.001). Between-group comparisons revealed a significantly greater 
reduction in Y-BOCS total score and score on obsession and compulsion subscales on 
Group A and Group B at all post-treatment measurement points compared to Group C (p 
< 0.001); but the 3 variables were not statistically different between Groups A and B at 
any post-treatment measurement points (p ≥ 0.053).  
 
Both Groups A and B had markedly higher rates of clinical response than Group C 
[89.2% (107/120) and 82.5% (99/120) vs. 67.5% (81/120), F = 18.283, df = 2, p < 0.001) 
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and remission [29.2% (35/120) and 22.5% (27/120) vs. 9.2% (11/120), F = 15.396, df = 
2, p < 0.001) (Fig. 4). No statistically significant differences were noted between Groups 
A and B in clinical response (F = 1.679, df = 1, p = 0.195) and remission rate (F = 1.066, 
df = 1, p = 0.302).       
 
3.3. Adverse events  
No severe adverse events were reported. The incidence of adverse events is summarized 
in Table 3. Both Group A and C exhibited significantly higher incidence of somnolence, 
tremor, dry mouth, blurred vision, constipation and laboratory test abnormality, the 
incidence was not significantly different in Group A and C.  
 
4. Discussion 
 
Serotonin reuptake inhibitors (SRIs), CBT, and their combination are first-line 
treatments for OCD (Pizarro et al., 2014; Romanelli et al., 2014). The first aim of the 
present study was to determine whether adding TEAS to the standard treatment could 
enhance the therapeutic response. We found that, while there was a significant 
improvement in OCD symptoms over the course of treatment in all three groups, the 
combination of three treatment regimens yielded much better outcomes compared with 
the standard treatment. That is, Group A had a significantly greater reduction in Y-
BOCS total scores and subscales for obsession and compulsion at all post-treatment 
measurement points than Group C. The clinical response and remission rates of Group A 
were also markedly higher than Group C; whereas the mean dosages of clomipramine 
taken and the incidence of adverse events were similar in the two groups. These results 
indicate that additional TEAS has superior efficacy compared to standard therapy 
without causing additional side effects.  
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SRI therapy often causes undesirable side effects (Murphy et al., 2008). The present 
study further examined whether CBT plus TEAS but without clomipramine could 
achieve better safety profile and comparable efficacy relative to clomipramine-contained 
treatment regimens. As expected, Group B experienced much fewer adverse events 
compared to the other two groups. The adverse events reported included somnolence, 
tremor, dry mouth, blurred vision, constipation and laboratory test abnormalities, all of 
which often occur in clomipramine and other SRI therapy (Murphy et al., 2008). On the 
other hand, Group B had a significantly greater reduction in symptom severity than 
Group C; the response and remission rates of Group B were also statistically greater than 
Group C, but not different from Group A. These results suggest that, while TEAS 
combined with CBT reduces adverse side effects associated with clomipramine, the 
therapeutic response achieved is comparable and even superior to that of the standard 
treatment. It appears that TEAS mainly augments the therapeutic efficacy of CBT. 
 
Modulation of brain serotonergic (5-HT) and related neuropeptidergic systems and 
normalization of sensorimotor gating may contribute to the effects of TEAS in 
improving OCD observed in the present study. Brain 5-HT systems are thought to play 
the principal role in the pathogenesis of OCD and related conditions; and SRI treatment 
effectively alleviates OCD symptoms (Camilla d'Angelo et al., 2014). Brain 
neuropeptides are also heavily involved in the development of obsessive thoughts and 
compulsive behavior, in particular vasopressin, oxytocin, adrenocorticotropic hormone 
(ACTH), corticotropin releasing factor (CRF), somatostatin and opioids; and SRIs are 
believed to also act these neuropeptide systems (McDougle et al., 1999). TEAS is 
thought to accelerate the synthesis and release of 5-HT and norepinephrine (NE) in the 
brain (Han, 2011). TEAS treatment may prevent lowering 5-HT and catecholamines in 
depressed patients (Markelova et al., 1985; Song et al., 2007) and in animal models of 
depression (Dos Santos et al., 2008), and potentiate antidepressant effects in depressed 
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patients (Yu et al., 2006, 2007). TEAS broadly modulates hypothalamic and limbic 
neuropeptide functions, in particular vasopressin and oxytocin (Han, 2011; Zhang et al., 
2012; Ulett et al., 1998). Thus, the improvement in OCD following combined treatment 
with clomipramine and TEAS may be due to additive effects on 5-HT and neuropeptide 
systems.  
 
Sensorimotor gating is the process by which a neural system (mainly cortico-striato-
thalamo-cortical circuits) screens or ‘filters’ extraneous external (sensory) and internal 
(cognitive, motor) impulses to prevent an overload of irrelevant information in the 
higher cortical centers of the brain (Ahmari et al., 2012). In OCD, impaired sensorimotor 
gating is postulated to cause cortical hyperexcitability and deteriorate inhibitory control, 
resulting in the inability to inhibit undesired thoughts and images (obsessions) and 
repetitive acts or reactions to uncontrollable obsessive thoughts (compulsions) (Ahmari 
et al., 2012; Kohl et al., 2013). CBT improves prepulse inhibition (PPI), an operational 
index of sensorimotor gating, in other psychiatric conditions (Ahmari et al., 2012; 
Kumari et al., 2012). Somatosensory evoked potentials (SEPs) is a potential biomarker 
for impaired sensorimotor gating of OCD patients (Rossi et al., 2005). Transcutaneous 
electrical nerve stimulation (TENS) on the median nerve induced SEPs, resulting in 
delayed gating effects on cortical response (Torquati et al., 2007). TENS also broadly 
modulated sensorimotor brain network activity, including the somatosensory cortex, 
basal ganglia, and thalamus (Choi et al., 2016; Dhond et al., 2008; Fang et al., 2009; 
Kara et al., 2010), and cortical neuronal excitability (Veldman et al., 2014). It appears 
that TENS, in particular TEAS, is capable of repairing ≥?filtering’ dysfunction of the 
sensorimotor gating via enhancing 5-HT and neuropeptide functions in related brain 
regions. Therefore, again the combination of interventions, in this case TEAS plus CBT, 
may reinforce the improvement in sensorimotor gating in OCD.       
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Several limitations of the current study should be considered. First, we did not include a 
group treated with clomipramine alone as a positive control; although Group B treated 
with placebo tablets served a negative control for pharmacotherapy. However, several 
studies have compared CBT, SRIs and their combination, and have shown limited 
efficacy of SRIs as monotherapy for OCD (Simpson et al., 2013). Second, a much 
smaller percentage of our patients had a diagnosis of comorbid psychiatric conditions 
compared to OCD studies of adults in the United States (Simpson et al., 2013). However, 
this reflects epidemiological findings which may be due to the diagnostic instruments 
used for comorbid conditions, as well as ethnic and psychological traits (Xiaoli et al., 
2014). One recent study has shown that only 15.2% children and adolescents had two or 
more psychiatric comorbid disorders in China (Xiaoli et al., 2014). Third, while the 
well-established dosing regimen of clomipramine was administered in the present study, 
the maximum dose was much lower than those previously reported, with a maximum of 
250-300 mg/day (Pizarro et al., 2014). This may represent an ethnic difference in 
tolerability to this drug, largely due to variations in cytochrome P450 enzymes (Lambert 
& Norman, 2013). Fourth, the sampling frame was mainly restricted to young adults 
recruited from local Chinese communities that may have distinctive perceptions on 
acupuncture therapy. Whether TEAS treatment outcomes are related to patients’ 
expectation and whether similar treatment outcomes could be achieved in OCD children 
and adolescents needs further investigation. Finally, a large portion of OCD patients 
may develop treatment-resistant cases who cannot achieve satisfactory improvement 
from CBT, SRIs, and even a combination of both (Tundo et al., 2007). However, the 
present did not analyze this subgroup. Whether the three component regimen could 
benefit treatment-resistant OCD deserves further evaluation.  
 
In summary, additional TEAS enhanced the efficacy of CBT and SRI combination 
therapy in OCD. TEAS combined with CBT reduced adverse side effects associated 
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with pharmacotherapy for OCD; the therapeutic response achieved was at least 
comparable and even superior to that of CBT and SRI combination therapy. The three 
component regimen can be considered an effective treatment option for OCD.    
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Legends for figures 
 
Fig. 1. Transcutaneous electrical acupoint stimulation (TEAS) on bilateral Nei-Guan 
(PC6) acupoints and cognitive-behavioral therapy (CBT) were conducted 
simultaneously for OCD patients. In this case, while TEAS was conducted on the 
patient’s hands (A), he was encouraged to hold trash can (B).     
 
Fig. 2. Flowchart of screening and recruitment of study subjects with OCD. Group A, 
transcutaneous electrical acupoint stimulation (TEAS) combined with cognitive-
behavioral therapy (CBT) plus clomipramine; Group B, TEAS combined with 
CBT plus placebo tablets; and Group C, simulated TEAS combined with CBT 
plus clomipramine.  
 
Fig. 3. The primary outcomes of OCD patients are illustrated with changes over the 12-
week course of treatment in the Yale-Brown Obsessive-Compulsive Scale (Y-
BOCS) total score and subscale for obsession and compulsion. Overall statistical 
significance was determined using the linear mixed-effect model analysis. Group 
A, transcutaneous electrical acupoint stimulation (TEAS) combined with 
cognitive-behavioral therapy (CBT) plus clomipramine; Group B, TEAS 
combined with CBT plus placebo tablets; and Group C, simulated TEAS 
combined with CBT plus clomipramine. * vs. Group C: p < 0.05. 
 
Fig. 4.  The rates of clinical response and remission in OCD patients. Group A, 
transcutaneous electrical acupoint stimulation (TEAS) combined with cognitive-
behavioral therapy (CBT) plus clomipramine; Group B, TEAS combined with 
CBT plus placebo tablets; and Group C, simulated TEAS combined with CBT 
plus clomipramine. Data were analyzed using Chi-square (χ2) test. * p < 0.05 vs. 
Group C.   
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Table 1 
 Baseline characteristics of OCD patients a 
Variables Group A (n = 120) 
Group B 
(n = 120) 
Group C  
(n = 120) 
t or χ2 
value P value 
Male, n (%) b 52 (43.3) 67 (55.8) 52 (43.3)  0.720 
Age (y) c 33.9 ± 11.7 31.9 ± 12.8 35.4 ± 12.6 2.510 0.083 
Duration of the illness, n (%) a      
≥1 years 55 (45.8) 52 (43.4) 61 (50.8) 3.141 0.535 
≥3 years 40 (33.4) 49 (40.8) 39 (32.5)   
≥10 years 25 (20.8) 19 (15.8) 20 (16.7)   
No. (%) of patients with comorbid 
psychiatric disorders b,d 
7 (5.8) 11 (9.2) 4 (3.3) 3.583 0.167 
No. (%) of patients with family members 
having severe mental problems b 
6 (5.0) 11 (9.2) 4 (3.3) 3.944 0.139 
No. (%) of patients under psychotropic 
medication when entry b,e  
90 (75.0) 78 (65.0) 77 (64.2) 4.012 0.135 
OCD symptom types, n (%) b      
Obsessional thoughts  72 (60.0) 77 (64.2) 72 (60.0) 0.586 0.746 
Compulsive behaviors 48 (40.0) 43 (35.8) 48 (40.0)   
Baseline Y-BOCS total score c 27.1 ± 4.9 26.9 ± 4.6 27.0 ± 3.7 0.080 0.923 
Baseline score on obsessive subscale c 14.1 ± 2.4  14.0 ± 2.4  13.8 ± 2.0 0.666 0.515 
Baseline score on compulsive subscale c 13.0 ± 2.8 12.9 ± 2.4 13.2 ± 2.0 0.625 0.536 
a
 Group A received transcutaneous electrical acupoint stimulation (TEAS) combined with cognitive-
behavioral therapy (CBT) plus clomipramine; Group B received TEAS combined with CBT plus 
placebo tablets; and Group C received simulated TEAS combined with CBT plus clomipramine. 
b
 Categorical data were analyzed using Chi-square (χ2) test. 
c
 Continuous data are expressed as mean ± SD and examined using one-way analysis of variance 
(ANOVA).  
d
 Comorbid psychiatric conditions included tic disorders, generalized anxiety disorders, and major 
depression.   
e
 Most patients were medicated with selective serotonin reuptake inhibitors (SSRIs) and 
antipsychotic agents. Y-BOCS, Yale-Brown Obsessive-Compulsive Scale. 
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Table 2 
Treatment outcomes measured using Y-BOCS in OCD patients a  
Variables 
Group A 
(n = 120) 
Group B 
(n = 120) 
Group C 
(n = 120) 
Overall analysis b___ 
F2,1794            p 
Total Y-BOCS score c    9.128 0.0001 
Baseline  27.1 ± 4.9 26.9 ± 4.6 27.0 ± 3.7   
Week 2 17.6 ± 2.48* 19.0 ± 2.4* 23.3 ± 3.5   
Week 4  14.8 ± 2.2* 16.4 ± 2.7* 20.1 ± 3.2   
Week 8 13.7 ± 2.7* 15.4 ± 2.9* 18.2 ± 3.0   
Week 12 13.2 ± 2.9* 14.8 ± 3.4* 16.7 ± 3.5    
Obsession severity    5.755 0.0032 
Baseline  14.1 ± 2.4 14.0 ± 2.4 13.8 ± 2.0   
Week 2 9.4 ± 1.4* 9.9 ± 1.3* 12.0 ± 2.1   
Week 4  8.0 ± 1.4* 8.6 ± 1.5* 10.3 ± 2.0    
Week 8 7.5 ± 1.6* 8.1 ± 1.6* 9.3 ± 2.0   
Week 12 7.2 ± 1.6* 7.8 ± 1.8* 8.6 ± 2.2   
Compulsive severity    13.389 <0.0001 
Baseline  13.0 ± 2.8 12.9 ± 2.4 13.2 ± 2.0   
Week 2 8.2 ± 1.7* 9.1 ± 1.4* 11.4 ± 2.1   
Week 4  6.8 ± 1.5* 7.8 ± 1.5* 9.8 ± 2.1   
Week 8 6.3 ± 1.7* 7.3 ± 1.6* 8.8 ± 1.9   
Week 12  5.9 ± 1.9* 7.0 ± 1.9* 8.2 ± 2.1   
a
 Group A received transcutaneous electrical acupoint stimulation (TEAS) combined with 
cognitive-behavioral therapy (CBT) plus clomipramine; Group B received TEAS 
combined with CBT plus placebo tablets; and Group C received simulated TEAS 
combined with CBT plus clomipramine. 
b
 Overall statistical significance was analyzed using a linear mixed-effect model analysis. 
Between-group differences were further evaluated using one-way analysis of variance 
(ANOVA). * vs. Group C: p < 0.05.   
c
 Y-BOCS, Yale-Brown Obsessive-Compulsive Scale. 
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Table 3 
The incidence of major treatment-emergent adverse events in OCD patients a  
Adverse event Group A (n = 120) 
Group B 
(n = 120) 
Group C 
(n = 120) χ
2
 value p value 
Somnolence  14 (11.7) 2 (1.7) 13 (10.8) 9.976 0.007 
Tremor  9 (7.5) 0 13 (10.8) 12.878 0.002 
Dry mouth 47 (39.2) 13 (10.8) 41 (34.2) 27.194 <0.001 
Blurred vision 23 (19.2) 8 (6.7) 15 (12.5) 8.424 0.015 
Constipation  24 (20.0) 8 (6.7) 28 (23.3) 13.440 0.001 
Dizziness  7 (5.8) 4 (3.3) 8 (6.7) 1.445 0.486 
Skin problems 11 (9.2) 12 (10.0) 9 (7.5) 0.480 0.787 
Laboratory test 
abnormality 
9 (7.5) 0 12 (10.0) 11.833 0.003 
a
 Group A received transcutaneous electrical acupoint stimulation (TEAS) combined with 
cognitive-behavioral therapy (CBT) plus clomipramine; Group B received TEAS combined with 
CBT plus placebo tablets; and Group C received simulated TEAS combined with CBT plus 
clomipramine. 
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Fig. 2 
 
 
 
Potentially met the inclusion criteria, but 
refused to participate (n = 588): 
 Unwilling to participate (231) 
 Refused to receive clomipramine (87) 
 Refused to receive CBT (134) 
 Refused to discontinue current 
medication (58) 
 Declined for other specified reasons (78) 
 
 Did not meet the inclusion 
criteria (n = 184) 
 Met the exclusion criteria  
(n =303) 
 
Screened  
(N = 1435) 
Randomization 
(N = 360) 
 
Group A (n = 120) Group B (n = 120) Group C (n = 120) 
Discontinued (n = 7): 
 Intolerance to drug side 
effects (3) 
 Intolerance to CBT (2) 
 Loss to follow-up (2) 
 
Discontinued (n = 8): 
 Intolerance to drug side 
effects (0) 
 Intolerance to CBT (7) 
 Loss to follow-up (1) 
 
Discontinued (n = 10): 
 Intolerance to drug side 
effects (9) 
 Intolerance to CBT (0) 
 Loss to follow-up (1) 
 
Completed  
(n = 113, 94.2%) 
Completed  
(n = 112, 93.3%) 
Completed  
(n = 110, 91.7%) 
Included in analysis 
(n = 120) 
Included in analysis 
(n = 120) 
Included in analysis 
(n = 120) 
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